| 摘要 |
#CMT# #/CMT# Method for screening for identifying sample having high probability of prothrombotic antiphospholipid antibodies, involves (a) mixing a sample from a patient with a platelet-containing reagent to give an assay mix, (b) adding a platelet activator to the assay mix, and (c) measuring platelet aggregation in the assay mix with an increase in platelet aggregation over the normal value in the assay mix indicating the presence of prothrombotic antiphospholipid antibodies in the patient's sample. #CMT#USE : #/CMT# The method is useful for screening for identifying sample having high probability of prothrombotic antiphospholipid antibodies which is useful for diagnosing antiphospholipid syndrome. #CMT#ADVANTAGE : #/CMT# The method is specific. #CMT#BIOTECHNOLOGY : #/CMT# Preferred Method: The patient's sample comprises platelet-rich plasma, platelet-poor plasma, serum, or whole blood. The platelet-containing reagent comprises suspension of isolated platelets in a buffer solution, platelet-rich plasma, or whole blood. The platelet activator comprises adenosine diphosphate, collagen, epinephrine, arachidonic acid and thrombin. The platelet aggregation in the assay mix is measured turbidimetrically, nephelometrically, or (i) passing the assay mix through a capillary and then through an opening of a separating element, and (ii) measuring the time required for a platelet clot to form at the opening of the separating element until the opening is closed. The rate of platelet aggregation in the assay mix is measured, preferably within 12-50 seconds after adding platelet activator to the assay mix, where the maximum rate of platelet aggregation is measured. The normal platelet aggregation is measured in a second assay in which a normal sample is mixed with the platelet-containing reagent to give an assay mix, where the ratio of the platelet aggregation measured in the assay mix in step (c) to the normal platelet aggregation is then formed, with a ratio greater than 1 which indicates presence of antiphospholipid antibodies in the patient's sample. #CMT#EXAMPLE : #/CMT# No suitable example given. |
